2023
Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas: An ILROG Multi-Institutional Study
Yegya-Raman N, Wright C, Ladbury C, Chew J, Zhang S, Sun S, Burke S, Baron J, Sim A, LaRiviere M, Yang J, Robinson T, Tseng Y, Terezakis S, Braunstein S, Dandapani S, Schuster S, Chong E, Plastaras J, Figura N. Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas: An ILROG Multi-Institutional Study. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: s50-s51. DOI: 10.1016/j.ijrobp.2023.06.333.Peer-Reviewed Original ResearchImmune effector cell-associated neurotoxicity syndromeProgression-free survivalCytokine release syndromeB-cell lymphomaChimeric antigen receptor T-cell therapySuperior progression-free survivalLarge B-cell lymphomaCAR-T infusionT-cell therapyMulti-institutional studyOverall survivalCTCAE v5.0T infusionTisa-celCAR TRefractory aggressive B-cell lymphomasStage III/IV diseaseT-cell/histiocyte-rich large B-cell lymphomaFavorable progression-free survivalCentral nervous system involvementDiffuse large B-cell lymphomaAggressive B-cell lymphomasPrimary mediastinal B-cell lymphomaMediastinal B-cell lymphomaNervous system involvement
2022
Magnesium sensing via LFA-1 regulates CD8+ T cell effector function
Lötscher J, Martí I Líndez AA, Kirchhammer N, Cribioli E, Giordano Attianese G, Trefny MP, Lenz M, Rothschild SI, Strati P, Künzli M, Lotter C, Schenk SH, Dehio P, Löliger J, Litzler L, Schreiner D, Koch V, Page N, Lee D, Grählert J, Kuzmin D, Burgener AV, Merkler D, Pless M, Balmer ML, Reith W, Huwyler J, Irving M, King CG, Zippelius A, Hess C. Magnesium sensing via LFA-1 regulates CD8+ T cell effector function. Cell 2022, 185: 585-602.e29. PMID: 35051368, DOI: 10.1016/j.cell.2021.12.039.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBacterial InfectionsCaloric RestrictionCD8-Positive T-LymphocytesCell Line, TumorCytotoxicity, ImmunologicHEK293 CellsHumansImmunologic MemoryImmunological SynapsesImmunotherapyLymphocyte ActivationLymphocyte Function-Associated Antigen-1MagnesiumMaleMAP Kinase Signaling SystemMice, Inbred C57BLNeoplasmsPhenotypePhosphorylationProto-Oncogene Proteins c-junConceptsLFA-1CAR TLow serum magnesium levelsMore rapid disease progressionAntibody-treated patientsRapid disease progressionShorter overall survivalSerum magnesium levelsCell effector functionsOverall survivalCellular immunityImmune synapse formationDisease progressionEffector functionsExtracellular magnesiumSpecific cytotoxicityMagnesium levelsSynapse formationCalcium fluxCell functionMetabolic reprogrammingCD8CellsNutrient sensingPatients
2018
Radiation Therapy As a Bridging Strategy for Refractory Diffuse Large B Cell Lymphoma Patients Awaiting CAR T Manufacturing of Axicabtagene Ciloleucel
Jain M, Chavez J, Shah B, Khimani F, Lazaryan A, Davila M, Liu H, Falchook A, Robinson T, Kim S, Locke F. Radiation Therapy As a Bridging Strategy for Refractory Diffuse Large B Cell Lymphoma Patients Awaiting CAR T Manufacturing of Axicabtagene Ciloleucel. Blood 2018, 132: 4220. DOI: 10.1182/blood-2018-99-117133.Peer-Reviewed Original ResearchCytokine release syndromeAxi-cel therapyCAR-T infusionCy conditioningCase seriesT infusionTumor burdenAxicabtagene ciloleucelCAR TSpeakers bureauRadiation therapyRefractory diffuse large B-cell lymphoma patientsRefractory diffuse large B-cell lymphomaChimeric antigen receptor T-cell therapyPatient experienced progressive diseaseSevere cytokine release syndromeDiffuse large B-cell lymphoma patientsDisease controlLarge B-cell lymphoma patientsB-cell lymphoma patientsDiffuse large B-cell lymphomaAdvisory CommitteeLarge B-cell lymphomaCAR T cell efficacyExperienced progressive disease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply